Tech Company Financing Transactions
Blade Therapeutics Funding Round
Blade Therapeutics, operating out of South San Francisco, raised $45 million from Deerfield Capital, MPM Capital and Novartis BioVenture Fund.
Transaction Overview
Company Name
Announced On
6/20/2016
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors
Deerfield Capital (Lead Investor) (Cameron Wheeler)
Pfizer Venture Investments (Elaine Jones)
Proceeds Purpose
Proceeds from the financing will be used to advance the selection and development of lead molecules designed to modify the pathobiology of fibrotic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
442 Littlefield Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Blade's novel target biology was discovered by its founder, Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wendye Robbins
Chief Technical Officer
Prabha Ibrahim
VP - Bus. Development
Felix Karim
VP - R & D
Maria Fuentes
Browse more venture capital transactions:
Prev: 6/20/2016: Rocketrip venture capital transaction
Next: 6/20/2016: Tigera venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs